Compare KALV & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALV | TRTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.7M | 720.8M |
| IPO Year | 2014 | N/A |
| Metric | KALV | TRTX |
|---|---|---|
| Price | $15.64 | $8.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $30.00 | $10.25 |
| AVG Volume (30 Days) | 564.9K | ★ 795.9K |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.35% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $108.37 | $0.86 |
| P/E Ratio | ★ N/A | $14.82 |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $6.47 |
| 52 Week High | $19.00 | $9.85 |
| Indicator | KALV | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 42.44 |
| Support Level | $14.45 | $8.55 |
| Resistance Level | $16.33 | $9.22 |
| Average True Range (ATR) | 0.69 | 0.21 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 80.05 | 37.35 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.